CURRICULUM VITAE – Marco Bisoffi, PhD

➔ PERSONAL and CONTACT INFORMATION

Date and place of birth: March 3, 1965, Basel, Switzerland.
Citizenship: US, Swiss, and Italian citizen.
Languages: English, German, Italian, and French: Fluent (speaking and writing).
Spanish: Knowledge.

Work address and contact information:
Chapman University
Schmid College of Science and Technology
Chemistry and Biochemistry
Keck Center for Science and Engineering, Office #235
450 N. Center Street
Orange, CA 92866
Tel. ++1 (714) 516-5961; Email: bisoffi@chapman.edu
Web page: http://www.chapman.edu/our-faculty/marco-bisoffi

➔ UNDERGRADUATE and GRADUATE EDUCATION (past to most recent)

1985-1990 Studies in Biology, University of Basel, Faculty of Natural Sciences, Switzerland: Courses in physics, chemistry, biochemistry, physiology, endocrinology, immunology, genetics, molecular biology, microbiology, neurophysiology, parasitology, plant physiology and biochemistry.

1990-1991 Diploma (MSc) thesis in Medical Parasitology, Laboratory of Biochemistry, Swiss Tropical Institute, University of Basel, Faculty of Natural Sciences, Switzerland. Supervision: Dr. B. Betschart (PhD). Title: *Identification of antigens recognized by the monoclonal antibody 46.08.76 directed against Brugia malayi infective larvae.*

1991 Academic Visitor, Imperial College of Science, Technology and Medicine, Department of Biochemistry, London, UK. Supervision: Dr. M.E. Selkirk (PhD).

1992-1995 PhD thesis in Biochemical and Molecular Parasitology, Laboratory of Biochemistry, Swiss Tropical Institute, University of Basel, Faculty of Natural Sciences, Switzerland. Supervision: Dr. B. Betschart (PhD). Title: *Isolation and characterization of cDNA clones coding for cuticular proteins of filariae and other parasitic nematodes.* Graduation with *summa cum laude.*

1993 Academic Visitor, International Institute of Genetics and Biophysics, Naples, Italy. Supervision: Dr. P. Bazzicalupo (PhD).

➔ POSTGRADUATE APPOINTMENTS / POSITIONS (most recent to past)

2013-present Associate Professor with Tenure and Co-Director of Chemistry and Biochemistry, Chapman University, Schmid College of Science and Technology, Keck Center for Science and Engineering, Orange, CA, USA; Joint Appointments with Biological Sciences, with Crean College of Health and Behavioral Sciences, and with Chapman University School of Pharmacy, Pharmaceutical Sciences. *Research: Molecular mechanisms of cancer development and progression; field cancerization, natural product based experimental therapeutics. Cancer types: Prostate, breast, pancreas.*

2006-2013 Assistant Professor, Flex-Track (2006-2009), Tenure Track (2009-2013), University of New Mexico Health Sciences Center, School of Medicine Department of Biochemistry and Molecular Biology; Albuquerque NM, USA. *Research: Molecular mechanisms of prostate and breast cancer development and progression; biomarker discovery and validation; experimental therapeutics.*

Research Specializations (2006-present; University of New Mexico [UNM] and Chapman University [CU])

Field cancerization in prostate and breast cancer: We study molecular alterations in structurally intact tissues adjacent to prostate adenocarcinomas, a phenomenon termed "field cancerization" or "field effect". These alterations include genetic and biochemical alterations. We hypothesize that: (i) field cancerization is a source of clinically useful biomarkers; (ii) field cancerization is a precursor of cancer (pre-malignancy); (iii) markers of field cancerization are targets for preventive intervention. Collaborations with Faculty at the UNM Department of Surgery, UNM Department of Pathology, UNM Office of Medical Investigator, Albuquerque Veterans Affairs Health Care System, University of California at Irvine (UCI) Department of Pathology and Laboratory Medicine, and the San Diego Vaccine Research Institute.
Media: http://www.youtube.com/watch?v=PqRSuuU00yE; https://blogs.chapman.edu/scst/2014/04/29/bisoffi-outside-tumor/, http://www.chapman.edu/our-faculty/marco-bisoffi.

This research has included the procurement of samples from patients consenting to donate remnant tissues for research. For this, I have coordinated the following Institutional Review Board (IRB) approved protocols, as regulated by the UNM Human Research Review Committee (HRRC):

HRRC #05-417: Prospective Evaluation of the Prognostic Value of Telomere DNA Content and Allelic Imbalance in Prostate Cancer.
HRRC #03-160: Molecular and Cellular Analyses of Human Prostate Tumors, their Adjacent Tissues, and Normal Prostatic Tissue.
HRRC #06-154 Retrospective Analysis of Telomere Content, Allelic Imbalance, and Field Cancerization in Prostate Cancer Biopsy Specimens at the Veterans Affairs Medical Center.
HRRC #02-536: Molecular and Cellular Analyses of Human Mammary Tumors and Adjacent Tissues.

At Chapman University, I have initiated IRB approved studies using human tissues from commercial sources. Eventually I will also work with tissues obtained through collaborations with Medical Centers in the area. Accordingly, I have established connections with investigators at the University of California Irvine, Department of Pathology, and at the Chao Family Comprehensive Cancer Center to establish possible collaborations involving human tissues from patients consenting to donate remnant tissues after surgical procedures.

Experimental therapeutics in prostate, pancreatic, and breast cancer: We study the effect of combichemical analogs of natural products on molecular targets in prostate, pancreatic, and breast cancer, including the androgen receptor (AR) and the early growth response 1 (EGR-1). We hypothesize that: (i) diarylpentanoid analogs of the diferuloylmethane (curcumin) induce oxidative stress, which leads to cancer cell death; (ii) down-regulation of androgen receptor (AR) by diarylpentanoid analogs leads to growth inhibition of advanced stage cancer; (iii) inhibition of AR and/or EGR-1 function by diarylpentanoid analogs inhibits tumorigenesis. Collaboration with Faculty at the Chapman University School of Pharmacy.
Recent Publications (PMID): 21796654.

Our research has been supported by the National Institutes of Health (NIH), New Mexico Cancer Center, the Department of Defense Prostate Cancer Program (DOD PCRP), Chapman University, and private parties.

2002-2006 Research Assistant Professor, University of New Mexico Health Sciences Center/School of Medicine, Department of Biochemistry and Molecular Biology, Albuquerque NM, USA. *Research: Molecular mechanisms of prostate and breast cancer progression, telomere biology.*

1998-2002 Research Assistant, University of Bern, Department of Clinical Research, Switzerland. *Research: In vivo phage display, molecular profiling of breast tumor vasculature, and molecular mechanisms of prostate cancer progression.* Supervision: Dr. G.N. Thalmann.

1998 Senior Postdoctoral Fellow, University of Basel, Institute of Medical Microbiology, and Gene Chip Laboratory at Hoffmann-La Roche Inc., Switzerland. *Research: Molecular mechanisms of carcinogenesis in mast cell tumors.* Supervision: Dr. C. Moroni.

1996-1998 Postdoctoral Fellow, University of New Mexico School of Medicine, Department of Biochemistry, Albuquerque NM, USA. *Research: Telomeres and telomerase in human cancer cell lines.* Supervision: Dr. J.K. Griffith.

➔ ADDITIONAL POSTGRADUATE TRAINING

Ongoing Biological and chemical safety training to maintain laboratory safety for all personnel, including students. Completed safety training modules include those from Chapman University (through the LearnUpon learning management system) and the Collaborative Institutional Training Initiative (CITI).

Ongoing Administrative training related to students and personnel. This includes topic such as student data confidentiality (Family Educational Rights and Privacy Act, FERPA), sexual harassment, discrimination, violence, etc.

2013 (Dec) "Flipped Class Workshop"; offered by the Institute for Excellence in Teaching, Chapman University.

2013 (Nov) Workshop in "Designing Scientific Teaching Tools for Biochemistry and Molecular Biology Education"; organized by the American Society for Biochemistry and Molecular Biology. University of San Diego, San Diego CA.

2013 (Aug) "Classroom Culture Workshop"; offered by the Institute for Excellence in Teaching, Chapman University.

2010 Grant Writing Workshop offered at the University of New Mexico Health Sciences Center by Dr. L.G. Hudson.

2005 (Oct) Biochemistry Education (BIOC 499); offered by Dr. W.L. Anderson and Dr. M.P. Osgood, University of New Mexico Health Sciences Center.

2004 (Apr) Proteomics (BIOC 624); offered by Dr. C.D. Mobarak, University of New Mexico Health Sciences Center.

2004 Workshop: Handling and Experimenting with Mice; offered by the University of New Mexico Health Sciences Center Animal Resource Facility.

2003 (Apr) Grants Management Workshop, University of New Mexico Health Sciences Center.

2003 (Apr) Tutor Training Workshop and Case Development Workshop at the University of New Mexico School of Medicine.

2002 Workshop: Introduction to the Use of GeneSpring, University of New Mexico Health Sciences Center.

2001 (Jun) Workshop: Introduction to Laboratory Animals; Animal Handling and Experiments, University of Bern, Switzerland.

2000 (Feb) Workshop: Leading of Teams and Work Groups, University of Bern, Switzerland.

1999 (Apr) Confocal Microscopy, University of Bern, Switzerland.

1996 (Mar) Radiation Protection Technology, University of New Mexico.

➔ TEACHING AND MENTORING EXPERIENCE

University of Bern, Switzerland

Lectures and Seminars

1998 Introduction to Immunology for laboratory technicians; 2 hours.
2000 (Feb) Applied Molecular Biology for urologists; 3 hours.
2001 (Jan) General and Applied Aspects of Gene Therapy (Graduate and Medical level); 2 hours.
2001 (Mar) Tumor Angiogenesis and Metastasis (Undergraduate level); 2 hours.

Mentoring

1998-2002 Supervision of 2 Undergraduate, and 2 Graduate students.
This activity resulted in several poster presentations and published manuscripts that included mentored students as authors.

Undergraduate: Genevieve Clement (1999), Michael Schmid (1999).
Graduate: Ekaterina Gresko (2001), Anita Finger (1998-2002).

University of New Mexico, USA

Lectures and Seminars

2001 (Oct) Biochemistry of Disease BIOC 463/563: Molecular Mechanisms of Metastasis. *Highest score in student evaluation among five instructors*; 9 hours.
2003 (Apr) Biochemical Methods BIOC 448L: Web-Based Genomics-Proteomics; 1 hour.
2003 (Nov) Biochemistry of Disease BIOC 463/563: Molecular Mechanisms of Metastasis. *Highest score in student evaluation among five instructors*; 9 hours.
2004 (Apr) Biochemical Methods BIOC 448L: Web-Based Genomics-Proteomics; 1 hour.
2004 (Nov) Biochemistry of Disease BIOC 463/563: Molecular Mechanisms of Metastasis. *Highest score in student evaluation among five instructors*; 9 hours.
2005 Biochemistry and Molecular Biology Journal Club/Seminar BIOC 548 (Course Director): 15 hours.
2005 (Apr) Biochemical Methods BIOC 448L: Web-Based Genomics-Proteomics; 1 hour.
2005 (Mar) Biochemical Methods BIOC 448L: Electrophoresis and Affinity Chromatography; 2 hours.
2005 (Fall) Introductory Biochemistry BIOC 423: Genetic Code and tRNA, Protein Synthesis I, and Protein Synthesis II; 3 hours.
2006 Biochemistry and Molecular Biology Journal Club/Seminar BIOC 548 (Course Director): 15 hours.

2006 (Mar) Cancer Biology BIOM 515: Prostate Cancer; 12 hours.
2006 (Apr) Biochemical Methods BIOC 448L: Web-Based Genomics-Proteomics; 1 hour.
2006 (Fall) Introductory Biochemistry BIOC 423: Thermodynamics/Enzymes, Enzyme Kinetics, Gene Expression/Regulation, Amino Acid Catabolism, Genetic Code and tRNA, Protein Synthesis I, and Protein Synthesis II; 22 hours.
2007 Biochemistry and Molecular Biology Journal Club/Seminar BIOC 548 (Course Director): 15 hours.
2007 (Spring) Introductory Biochemistry BIOC 423: Amino Acid Synthesis and Catabolism; 5 hours.
2007 (Mar) Cancer Biology BIOM 515: Prostate Cancer; 12 hours.
2007 (Apr) Biochemical Methods BIOC 448L: Web-Based Genomics-Proteomics; 1 hour.
2008 Biochemistry and Molecular Biology Journal Club/Seminar BIOC 548 (Course Director): 15 hours.
2008 (Spring) Biochemistry of Disease BIOC 464/564: Molecular Mechanisms of Metastasis; 9 hours.
2008 (Spring) Cancer Biology BIOM 515: Prostate Cancer; 12 hours.
2008 (Apr) Biochemical Methods BIOC 448L: Web-Based Genomics-Proteomics; 1 hour.
2009 (Spring) Cancer Biology BIOM 515 (Course Director): Prostate Cancer; 12 hours.
2009 (Spring) Experimental Design and Methods in Molecular and Cellular Biosciences BIOM 522: Gene Expression; 3 hours.
2009 (Apr) Biochemical Methods BIOC 448L: Web-Based Genomics-Proteomics; 1 hour.
2010 (Spring) Cancer Biology BIOM 515 (Course Director): Prostate Cancer; 12 hours.
2010 (Spring) Experimental Design and Methods in Molecular and Cellular Biosciences BIOM 522: Gene Expression, Web-Based Genomics-Proteomics; 3 hours.
2010 (Apr) Biochemical Methods BIOC 448L: Web-Based Genomics-Proteomics; 1 hour.
2010 (Fall) Biochemistry of Disease BIOC 463/563: Molecular Mechanisms of Metastasis; 9 hours.
2011 (Spring) Experimental Design and Methods in Molecular and Cellular Biosciences BIOM 522: Gene Expression, Web-Based Genomics-Proteomics; 3 hours.
2011 (Apr) Biochemical Methods BIOC 448L: Web-Based Genomics-Proteomics; 1 hour.
2011 (Spring) Cancer Biology BIOM 515 (Course Director): Prostate Cancer; 15 hours.
2011 (Fall) Biochemistry of Disease BIOC 463/563: Molecular Mechanisms of Metastasis; 9 hours.
2012 (Apr) Biochemical Methods BIOC 448L: Web-Based Genomics-Proteomics; 1 hour.
2012 (Spring) Experimental Design and Methods in Molecular and Cellular Biosciences BIOM 522: Gene Expression, Web-Based Genomics-Proteomics; 3 hours.
2012 (Spring) Cancer Biology BIOM 515 (Course Director): Prostate Cancer; 15 hours.

Tutorials

2002 (Fall) Co-Tutor in UNM School of Medicine GI/Nutrition Block; 36 hours.
2003 (Fall) Tutor in UNM School of Medicine GI/Nutrition Block; 36 hours.
2004 (Fall) Tutor in UNM School of Medicine GI/Nutrition Block; 36 hours.
2004 (Fall) Tutor in UNM School of Medicine Genetics-Neoplasia Block; 36 hours.
2005 (Fall) Tutor in UNM School of Medicine GI/Nutrition Block; 36 hours.
2005 (Fall) Facilitator/Tutor in Online Tutorial of BIOC 423: Introductory Biochemistry.

Laboratory Courses

2005 (Spring) Biochemical Methods BIOC 448L: Electrophoresis and Affinity Chromatography; 20 hours.
2008 (Spring) Biochemical Methods BIOC 448L: DNA Analysis and Forensics; 20 hours.

Mentoring

2002-2013 (Co)-mentoring and supervision of 32 Undergraduate, 16 Graduate, 2 Postgraduate, 8 Medical students, and 2 physicians in various UNM Programs, including: (i) Pathways to Breast Cancer Program (PI: Dr. J.K.

Griffith); (ii) Minority Access to Research Careers (MARC) Program; (iii) Post-baccalaureate Research Education Program (PREP); (iv) National Institute of Diabetes and Digestive and Kidney (NIDDK) Undergraduate Short-Term Education Program for Underrepresented Persons (STEP-UP), and the Undergraduate Pipeline Network (UPN). *This activity resulted in several poster presentations and published manuscripts that included mentored students as authors (see below).*

Undergraduate: Christopher Heaphy (2003), co-supervision (PI: Dr. J.K. Griffith), Brigitte Holder (2003), co-supervision (PI: Dr. J.K. Griffith), Paul Durfee (2002), Jennifer Smith (2003), Jessica Wyaco (2003), co-supervision (PI: Dr. J.K. Griffith), Alexandra Fajardo (2004), Brianna Bodo (2004), Kimberly Butler (2004), co-supervision (PI: Dr. J.K. Griffith), Robert Griffith (2006), Christopher Giron (2006), co-supervision (PI: Dr. J.K. Griffith/Dr. K.A. Trujillo), Haily Lee (2007), Robert Buckley (2007), Vincent Metzger (2007), Lindsay Candelaria (2008), Rahman Johnson (2008), Keith Vargas (2008), co-supervision (PI: Dr. J.K. Griffith/Dr. K.A. Trujillo), Minh Mai, co-supervision (PI: Dr. J.K. Griffith/Dr. K.A. Trujillo), Nathaniel Hodoba (2008), Travis Williams (2008), Monica Avila (2009), co-supervision (PI: Dr. J.K. Griffith/Dr. K.A. Trujillo), Alaa Maoued (2009), America Moreno (2009), Anna Jones (2009), Griffin Ernst (2010), Robin Willard (2010), Randi Garcia (2010), co-supervision (PI: Dr. K.A. Trujillo), Christopher Plaman (2010), Samuel Hatfield (2011), Akindele Abosede (2012), Stephanie Logothetis (2012), co-supervision (PI: Dr. V.O. Shah), Katharine Juarez (2012, co-supervision (PI: Dr. V.O. Shah), Dung Tien Nguyen (2012).

Graduate: William Hines (2002), co-supervision (PI: Dr. J.K. Griffith), Kimberly Butler (2005), co-supervision (PI: Dr. J.K. Griffith), Christopher Heaphy (2007), co-supervision (PI: Dr. J.K. Griffith), Alexandra Fajardo (2007), Njotu Agbor (2007), rotation student, Ramesh Kaini (2007), rotation student, Hong Zhao (2008), co-supervision (PI: Dr. D. Dunaway-Mariano), Robert Taylor (2008), partial supervision (PI: Dr. L.O. Sillerud), Lizath Aguiniga (2009), Brittany Garcia (2009), Jaclyn Murton (2010), rotation student, Gloria Herrera (2010), Miguel Barberena (2011-2012), Roger Vaughan (2011-2012), co-supervision (PI: Dr. C.A. Conn), Randi Garcia (2011-2013), co-supervision (PI: Dr. K.A. Trujillo), Lucia Tome (2012), Jamie Garcia (2012)

Postgraduate: Kelly Higgins (2006-2007), Robert Taylor (2011-2013), co-supervision (PI: Dr. L.O. Sillerud).

Medical: Adrian Maestas (2005), Christina Haaland (2008), co-supervision (PI: Dr. J.K. Griffith), Eric Treat (2007), co-supervision (PI: Dr. A. Y. Smith), Dr. Zorisadday Gonzalez (2009), Dr. Jonathan Danaraj (2010 and 2011), Anna Jones (2012), Heidi Overton (2012), Sara Russel (2012), Kresta Antillon (2012), Shannon Jenkins (2012).

Training

2006-2013 Training of 4 laboratory technicians (UNM HSC grade 9-11): Ming Ji (2006-2009), Trisha Fleet (2007-2010), Virginia Severns (2009-2013), Anna Jones (2010).

Chapman University, USA

Lectures and Laboratory Courses

2013 (Fall) BIOL/BCHM 209L: Introduction to Molecular Genetics; Laboratory; 120 hours.
2014 (Spring) BIOL/BCHM 436 and 436L: Molecular Genetics; Lecture and Laboratory; 96 hours.
2014 (Spring) BCHM 320: Bioengineering and Biotechnology; 1 hour.
2014 (Fall) BIOL/BCHM 208L: Introduction to Molecular Genetics; Laboratory; 120 hours.
2014 (Fall) HONORS class; subject covered: “Telomeres and Aging”; 1 hour.
2015 (Spring) BIOL/BCHM 436 and 436L: Molecular Genetics; Lecture and Laboratory; 96 hours.
2015 (Fall) BCHM 335L: Biochemistry I-Biomolecules; Laboratory; 120 hours.
2016 (Spring) BCHM 320: Bioengineering and Biotechnology; 1 hour.
2016 (Spring) BIOL/BCHM 436: Molecular Genetics; Lecture; 30 hours.

2016 (Fall) BCHM 335 and 335L: Biochemistry I-Biomolecules; Lecture (co-teaching); 105 hours.
2016 (Fall) BIOL/BCHM 401: Cancer Biology; Lecture (co-teaching); 30 hours.
2017 (Spring) BIOL/BCHM 436: Molecular Genetics; Lecture; 30 hours.
2017 (Fall) BCHM 335 and 335L: Biochemistry I-Biomolecules; Lecture; 45 hours.
2017 (Fall) BIOL/BCHM 401: Cancer Biology; Lecture (co-teaching); 30 hours.
2018 (Spring) BIOL/BCHM 436: Molecular Genetics; Lecture; 30 hours.
2018 (Spring) BCHM 320: Bioengineering and Biotechnology; 1 hour.
2018 (Fall) BCHM 335 and 335L: Biochemistry I-Biomolecules; Lecture; 45 hours.
2018 (Fall) BIOL/BCHM 401: Cancer Biology; Lecture (co-teaching); 30 hours.

Mentoring

2013-present (Co)-mentoring and supervision of 45 Undergraduate, 2 Graduate, and 1 Postdoctoral students enrolled in various Chapman University programs. *This activity resulted in several poster presentations and published manuscripts that included mentored students as authors (see below).*

Undergraduate: Dor Shoshan (2013-2015), Emily Frisch (2013-2016), Julie King (2013-2015), Kristin Gabriel (2013-2015), Homa Hayatifar (2013-2015), Lijah Vann Gardner (2013-2016), Ashley Forman (2014-2015), Kristen Yu (2013), Hany Lobos (2014), Nicole Hollenbeck (2014-2015), Amir Olfat (2014), Jonathan Redrico (2014), Jenny Park (2014), Julie Nguyen (2015-2017), Brandon Morse (2016-2017), Victor Levy (2015-2016), Jonathan Woo, co-supervision (PI: Dr. Christopher Kim; 2014-2015), Jack Jacobs, co-supervision (PI: Dr. Christopher Kim; 2014-2015), Jeremy Feck, co-supervision (PI: Dr. William Wright; 2015), Kory Cablay, co-supervision (PI: Dr. Christopher Kim; 2015), Cynthia Kakish (2015), Haili Coffin (2015-2017), Rima Sanyal (2015-2017), Taryn Miyake, co-supervision (PI: Dr. Melissa Rowland-Goldsmith; 2015-2017), Caileen Sylvester (2015-2017), Nicole Choy, co-supervision (PI: Dr. Dan Wellman; 2017), Ana Kalyta, co-supervision (PI: Dr. William Wright; 2015-2016), Chrys-Michel Esseau-Thomas (2016), Ori Barashy (2016), Anthony Torossian, co-supervision (PI: Dr. Christopher Kim; 2016), Zach Ellis, co-supervision (PI: Dr. Jason Keller; 2016), Kelsey Leavy (2017), Philip Pytak (2016-2018), Emily Cauble (2017-present), Avrita Brar (2017-present), Parvin Mahdipoor (2017), Alexandra Solis (2017-present), Samantha Dyer (2017-present), Emma Whitely (2017-present), Emma Beale (2017-present), Abbigael Eli (2018-present), Jarett Guillow (2018-present), Erika Vazquez (2018-present), Alex Graden (2018-present), Daisy Haas (2018-present).

Graduate: Paul Park, co-supervision (PI: Dr. Rakesh Tiwari), Stephanie Stout, co-supervision (PI: Dr. Elysia Davis).

Postgraduate: Neda Sadeghiani-Pelar (2015).

➔ HONORS, AWARDS, RECOGNITIONS

1995 Swiss National Research Foundation Fellowship.
1996 CIBA-Geigy Research Foundation Fellowship.
1996 Swiss Cancer League/Cancer Research Switzerland Fellowship.
2001 Novartis Research Foundation Award.
2002 University of New Mexico Research Allocation Committee Award.
2003 American Cancer Society Institutional Research Award.
2004 University of New Mexico Research Allocation Committee Award.
2004 New Mexico Idea Network of Biomedical Research Excellence Award.
2009 New Mexico Idea Network of Biomedical Research Excellence Award.
2010 R&D Magazine's Top 100 Technologies Award.

2013 University of New Mexico, Health Sciences Center, Department of Biochemistry and Molecular Biology, Adjunct Faculty status.
2013 Chapman University, Crean College of Health and Behavioral Sciences, Joint Appointment.
2013 University of California at Irvine, Chao Family Comprehensive Cancer Center, Associate Member.
2014 Chapman University, School of Pharmacy, Joint Appointment.
2016 Distinguished Research, Scholarship and Creative Activity Award from the Research and Sponsored Programs Administration.
2016 Outstanding Contribution to Research Award from the Chapman University School of Pharmacy.
2016 Co-Teaching Award for the upper division BCHM/BIOL elective 401: Cancer Biology (with Dr. M. Rowland-Goldsmith) from the Chapman University Faculty Research and Development Council.
2018 Achievement Award for Unit Faculty Excellence in teaching, creative/scholarly activity, or service from the Chapman University Office of the Provost.

➔ EDITORIAL BOARDS

2005-present Reviewer for the Congressionally Directed Medical Research Programs, Department of Defense Prostate Cancer Research Program.
2006-present Reviewer for the Congressionally Directed Medical Research Programs, Department of Defense Breast Cancer Research Program.
2014-present Reviewer for the National Institutes of Health, National Cancer Institute, Center for Scientific Review (CSR).
2005 Reviewer for the James and Esther King Medical Research Foundation, Florida.
2005 Reviewer for the Ben Franklin Technology Partners-Pennsylvania Nanotechnology Institute, Pennsylvania.
2006 Reviewer for the Bankhead-Coley Cancer Research Program, Florida.
2005-present Reviewer for *BioEssays, Cancers, Cancer Letters, Clinical Experimental Metastasis, Neoplasia, Bioorganic and Medicinal Chemistry Letters, PLoS, Journal of Cellular Biochemistry, Journal of Urology, Biosensors and Bioelectronics, The International Journal of Cancer*, *The International Journal of Oncology, Letters in Drug Design & Discovery*, *Genome Research, Molecular Carcinogenesis*, *Lancet Oncology*, and several others.
2013-2016 Member of the Editorial Board for Journal of Cancer Research (Hindawi Publishing Corporation; Nasr City, Cairo, Egypt and New York, NY, USA).

➔ PROFESSIONAL MEMBERSHIPS AND AFFILIATIONS

- American Association for Cancer Research.
- American Society for Biochemistry and Molecular Biology.
- Society for Basic Urologic Research.
- American Chemical Society.

➔ INTERNAL REVIEW, ACADEMIC AND ADVISING BOARDS

2004-2013 Member of the New Mexico Cancer Center.
2004-2013 Member of the Breast Multidisciplinary Working Group, New Mexico Cancer Center.
2004-2013 Member of the Breast Multidisciplinary Protocol Development Subgroup, New Mexico Cancer Center.
2004-2009 Chair of the Breast Multidisciplinary Protocol Development Subgroup, New Mexico Cancer Center.
2004-2012 Member of the Genitourinary/Prostate Multidisciplinary Working Group, New Mexico Cancer Center.
2007-2012 Co-chair of the Genitourinary/Prostate Multidisciplinary Working Group, New Mexico Cancer Center.

2005-2013 Member of the Women's (and Hormone Responsive) Cancer Research Program, New Mexico Cancer Center.
2005-2013 Member of the University of New Mexico Health Sciences Center Institutional Biosafety Review Committee.
2005-2013 Member of the University of New Mexico Health Sciences Center Scientific Research Committee of the Human Tissue Repository Oversight Committee.
2006-2013 Member of the University of New Mexico Health Sciences Center Biomedical Sciences Graduate Program Steering Committee.
2006-2013 Member of the University of New Mexico Health Sciences Center Biomedical Sciences Graduate Program Admissions Review Committee.
2009-2013 Representative of the University of New Mexico Health Sciences Center Cancer Research Program in the University of New Mexico Health Sciences Center Biomedical Sciences Graduate Program Steering Committee.
2009-2013 Member of the University of New Mexico Clinical and Translational Science Center, Participant and Clinical Interactions Resource advisory Committee.
2011-2013 Member of the New Mexico Cancer Nanoscience and Microsystems Training Center.
2012-2013 Advisory Council Member of the University of New Mexico Health Sciences Center/Clinical Translational Science Center Undergraduate Pipeline Network.
2005-2013 Committee Member for Graduate Students of the University of New Mexico Health Sciences Center Biomedical Sciences Graduate Program.
2013-present Member and Chair of the Chapman University Institutional Biosafety Review Committee.
2014-present External evaluator of Faculty recruitment for the Chapman University School of Pharmacy.
2014-present Member of the Genitourinary Disease Oriented Team of the University of California at Irvine (UCI) Chao Family Comprehensive Cancer Center.
2015-present Member of the Schmid College of Science and Technology Curriculum Committee.
2015-present External evaluator of Faculty recruitment for Schmid College of Science and Technology at Chapman University.
2015 Review Coordinator of the Chapman University Research Integrity Policy for Schmid College of Science and Technology.
2015-present Committee Member for graduate students of the Chapman University School of Pharmacy Pharmaceutical Sciences Graduate Program.
2016-2017 Senator for the Schmid College of Science and Technology in the Chapman University Faculty Senate.
2016-present Faculty participant/advisor in the Schmid Student Leadership Council (SSLC)
2018 Reviewer of the Chapman University Faculty Opportunity Funds.
2018-present Member of the Chapman University Pre-health Advising Committee and Faculty advisor for the pre-veterinarian student club.

➔ EXTRACURRICULAR (COMMUNITY OUTREACH) ACTIVITIES

2004 Judge, Rio Rancho High School Science Fair.
2006 Judge, Rio Rancho High School Science Fair.
2007 Judge, INTEL International Science Fair.
2007 Judge, UNM Science and Engineering Research Fair.
2015 Public Speaker for the American Cancer Society, Southern California Section.
2015 Judge, Orange County Science and Engineering Fair.
2016 Public Speaker at the Osher Lifelong Learning Institute at the California State University Fullerton.
2016 Public Speaker at the Nicholas Academy in Santa Ana.

➔ PEER-REVIEWED RESEARCH SUPPORT (grants awarded as principal investigator and co-investigator)

Bisoffi, Marco, 06/01/2014 to 03/31/2017.
Chapman University start-up funds to establish Laboratory for Biomedical Research with Focus on Cancer Biology.
Role: PI.

Bisoffi, Marco, 01/01/2014-continuing.
Chapman University Office for Undergraduate Research; support for individual projects / undergraduate students in two major research areas: "Molecular pathways of field cancerization" and "Diarylpentanoid analog based experimental therapeutics".
Role: PI.

Bisoffi, Marco, 06/01/2014-08/31/2014.
Chapman University Office for Undergraduate Research; Summer Undergraduate Research Fellowship grant (awarded to Dor Shoshan).
Field cancerization – Thinking outside of the tumor: Association analyses of markers of prostate oncogenesis.

Bisoffi, Marco, 06/01/2015-08/31/2015.
Chapman University Office for Undergraduate Research; Summer Undergraduate Research Fellowship grant (awarded to Kristin Gabriel).
The role of exosomes in prostate field cancerization.

Bisoffi Marco, 06/01/2016-08/31/2016.
Chapman University Office for Undergraduate Research; Summer Undergraduate Research Fellowship grant (awarded to Seth Yund).
Genetic expression profiling of Bifidobacterium longum during gliadin digest.

Bisoffi Marco, 06/01/2018-08/31/2018.
Chapman University Office for Undergraduate Research; Summer Undergraduate Research Fellowship grant (awarded to Emily Cauble).
The role of gain-of-function p53 mutations in prostate field cancerization.

Bisoffi, Marco, 03/25/2015 to 02/28/2017; $103,500 per year (total direct and indirect costs; on no-cost extension).
DOD Prostate Cancer Research Program.
The role of exosomes in prostate field cancerization.
Role: PI.

Bisoffi, Marco, 07/01/2009 to 06/30/2014; $112,500 per year (total direct and indirect costs).
NIH Idea Network for Biomedical Research Excellence.
Biomarker and Target Discovery in Human Prostatic Tissues, an Integrated Approach.
Role: PI.

Sillerud, Laurel, 01/01/2007 to 31/12/2011.
NIH RO1.
Development of Novel Imaging Methods for Prostate Cancer.
Role: Co-investigator.

Bisoffi, Marco, 07/01/2008 to 06/30/2011; $112,500 per year (total direct and indirect costs).
NIH/NCI RO3 Cancer Prevention Research Small Grant.
Targeting Egr-1 with Curcumin Analogs for Prostate Cancer Prevention.
Role: PI.

Bisoffi, Marco, 05/01/2005 to 06/30/2009; $112,500 per year (total direct and indirect costs).
NIH Idea Network for Biomedical Research Excellence.
Markers of Prostate Cancer Progression: A Telomere-Based Proteomic Approach.
Role: PI.

Bisoffi, Marco, 11/01/2006 to 10/31/2007; $112,500 per year (total direct and indirect costs).
DOD Prostate Cancer Research Program.
Curcumin Based Drug Screening for Inhibitors of NF kappa B in a Cell Model of Prostate Cancer Progression.
Role: PI.

Larson, Richard, 04/01/2009 to 03/31/11.
University of California at Davis/Lawrence Livermore National Laboratory Point-of-Care Center.
Point-of-care Multiplex Pathogen Detection by Surface Acoustic Wave Biosensors.
Role: Co-investigator.

Griffith, Jeffrey, 12/01/2004 to 11/30/2007.
DOD Breast Cancer Research Program.
Prognostic Significance of Telomere Attrition in Ductal Carcinoma In Situ of the Breast.
Role: Co-investigator.

Bisoffi, Marco, 10/01/2004 to 09/30/2006; $25,000 per year.
Research Allocation Committee, University of New Mexico Health Sciences Center.
The Kinase-Like Protein GS3955: A Marker of Prostate Cancer Progression?
Role: PI.

Bisoffi, Marco, 10/01/2002 to 09/31/2003; $25,000 per year.
Research Allocation Committee, University of New Mexico Health Sciences Center.
The Role of Kinase-Like Protein GS3955 in Prostate Cancer Progression.
Role: PI.

Bisoffi, Marco, 01/01/2003 to 31/31/2003; $25,000 per year.
American Cancer Society.
The Role of Kinase-Like Protein GS3955 in Prostate Cancer Progression.
Role: PI.

Bisoffi, Marco, 01/01/2001 to 12/31/2001.
Novartis Research Foundation, Switzerland; $40,000 per year.
Identification of Differentially Expressed Genes in Androgen-Independent and Metastatic Prostate Cancer Cells.
Role: PI.

Griffith, Jeffrey, 04/01/2000 to 03/31/2005.

NIH/NCI R33.
Prognostic Value of Telomere DNA in Prostate Biopsy.
Role: Co-Investigator.

Stadler, Beda and Cecchini, Marco, 2000.
Swiss National Science Foundation, Continuation of Program 37 "Somatic Gene Therapy", Switzerland.
Identification of molecular targets on tumor and bone marrow vasculature for gene delivery purposes using phage display and expression profiling.
Role: Co-Investigator.

Thalmann, George, 1999.
Swiss National Science Foundation, Switzerland.
Identification of molecular determinants of prostate cancer progression and bone predilection of metastatic cells.
Role: Co-Investigator.

➔ PUBLICATIONS

Journal Publications

1. Bisoffi M, Betschart B. Isolation and sequence comparison of a cuticular collagen of *Brugia pahangi*. *Parasitology* (1996), 113: 145-155.
2. Bisoffi M, Marti S, Betschart B. Repetitive peptide motifs in the cuticlin of *Ascaris suum*. *Molecular and Biochemical Parasitology* (1996), 80: 55-64.
3. Bisoffi M, Betschart B. *Ascaris suum*: Molecular cloning of an intermediate filament of *Ascaris suum*. *International Health and Tropical Medicine* (1996), 1: 640-645.
4. Bisoffi M, Chakerian AE (shared first authorship), Fore ML, Bryant JE, Moyzis RK, Griffith JK. Inhibition of human telomerase by a retrovirus expressing telomeric antisense RNA. *European Journal of Cancer* (1998), 34: 1242-1249.
5. Finger AN, Bisoffi M, Wetterwald A, Gautschi E, Hohenfeld U, Klima I, Stadler BM, Mazzucchelli L, Thalmann GN, Cecchini MG. Scavenger receptor block as strategy for the identification of bone marrow homing phages by panning *in vivo* random peptide phage displayed libraries. *Journal of Immunological Methods* (2002), 264: 173-186.
6. Adsan O, Cecchini MG, Bisoffi M, Wetterwald A, Klima I, Danuser HJ, Studer UE, Thalmann GN. Can the reverse transcriptase-polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen improve staging and predict biochemical recurrence? *BJU International* (2002), 90: 579-585.
7. Schmid MC, Bisoffi M (shared first authorship), Wetterwald A, Gautschi E, Thalmann GN, Mitola S, Bussolino F, Cecchini MG. Insulin-like growth factor binding protein-3 (IGFBP-3) is highly expressed in endothelial cells of neoangiogenic mouse tumor vessels. *International Journal of Cancer* (2003), 103: 577-586.
8. Clément G, Bisoffi M (shared first authorship), Finger AN, Wetterwald A, Thalmann GN, Cecchini MG. Peptabodies as tools to test ligands isolated from phage displayed peptide libraries. *Journal of Immunological Methods* (2003), 276: 135-141.
9. Bisoffi M, Klima I, Gresko E, Durfee PN, Hines WC, Griffith JK, Studer UE, Thalmann GN. Expression profiles of androgen-independent bone metastatic prostate cancer cells indicate over-expression of the putative serine-threonine kinase GS3955. *Journal of Urology* (2004), 172: 1145-1150.
10. Hines WC, Fajardo AM, Joste NE, Bisoffi M, Griffith JK. Quantitative and spatial measurements of telomerase reverse transcriptase expression within normal and malignant human breast tissues. *Molecular Cancer Research* (2005), 3: 503-509.
11. Heaphy CM, Bisoffi M, Fordyce CA, Haaland-Pullus CM, Hines WC, Joste NE, Griffith JK. Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. *International Journal of Cancer* (2006), 119: 108-116.

12. Fordyce CA, Heaphy CM, Joste NE, Bisoffi M, Wyaco JL, Joste NE, Mangalik A, Baumgartner KB, Baumgartner RN, Hunt WC, Griffith JK. Telomere content correlates with stage and prognosis in invasive breast cancer. *Breast Cancer Research and Treatment* (2006), 99: 193-202.
13. Bisoffi M, Heaphy CM, Griffith JK. Telomeres: Prognostic markers for solid tumors. *International Journal of Cancer* (2006), 119: 2255-2260.
14. Liu Z, Dai D, Bisoffi M, Heaphy C, Leslie K, Griffith JK and Hu CA. A novel loss-of-function mutation in TP53 in endometrial cancer. *Molecular and Cellular Biochemistry* (2007), 297: 179-187.
15. Heaphy CM, Hines WC, Butler KS, Haaland CM, Heywood G, Fischer EG, Bisoffi M, Griffith JK. Assessment of the frequency of allelic imbalance in human tissue using a multiplex polymerase chain reaction system. *Journal of Molecular Diagnostics* (2007), 9: 266-271.
16. Serda RE, Adolphi NL, Bisoffi M, Sillerud LO. Targeting and cellular trafficking of magnetic nanoparticles for prostate cancer imaging. *Molecular Imaging* (2007), 6: 277-288.
17. Heaphy CM, Bisoffi M, Griffith JK. Diagnostic significance of allelic imbalance in cancer. *Expert Opinion on Medical Diagnostics* (2007), 1(2): 159-168.
18. Heaphy CM, Baumgartner KB, Bisoffi M, Baumgartner RN, Griffith JK. Telomere DNA content predicts breast cancer-free survival interval. *Clinical Cancer Research* (2007), 13(23): 7037-7043.
19. Serda RE, Bisoffi M, Thompson TA, Ji M, Omdahl JL, Sillerud LO. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells. *Prostate* (2008), 68(7): 773-783.
20. Bisoffi M, Hjelle B, Brown DC, Branch DW, Edwards TL, Brozik SM, Bondu-Hawkins VS, Larson RS. Detection of viral bioagents using a shear horizontal surface acoustic wave biosensor. *Biosensors and Bioelectronics* (2008), 23(9): 1397-1403.
21. Heaphy CM, Bisoffi M, Joste NE, Baumgartner KB, Baumgartner RN, Griffith JK. Genomic Instability demonstrates similarity between DCIS and invasive carcinomas. *Breast Cancer Research and Treatment* (2009), 117(1): 17-24.
22. Treat EG, Heaphy CM, Massie LW, Bisoffi M, Smith AY, Davis MS, Griffith JK. Telomere DNA content in prostate biopsies predicts early rise in prostate specific antigen following radical prostatectomy for prostate cancer. *Urology* (2010), 75(3): 724-729.
23. Haaland CM, Heaphy CM, Butler KS, Fischer EG, Griffith JK, Bisoffi M. Differential gene expression in tumor adjacent histologically normal prostatic tissue indicates field cancerization. *International Journal of Oncology* (2009), 35(3): 537-546.
24. Zhao H, Martin BM, Bisoffi M, Dunaway-Mariano D. The C-Terminal Akt Modulatory Protein (CTMP) is an Acyl-CoA Thioesterase of the Hotdogfold Family. *Biochemistry* (2009), 48(24): 5507-5509.
25. Heaphy CM, Griffith JK, Bisoffi M. Mammary field cancerization: molecular evidence and clinical importance. *Breast Cancer Research and Treatment* (2009), 118(2): 229-239.
26. Van Slambrouck S, Hilkens J, Bisoffi M, Steelant WF. AsialoGM1 and integrin alpha2beta1 mediate prostate cancer progression. *International Journal of Oncology* (2009), 35(4): 693-699.
27. Heaphy CM, Fleet TM, Treat EG, Lee SJ, Smith AY, Davis MS, Griffith JK, Fischer EG, Bisoffi M. Organ-wide telomeric status in diseased and disease-free prostatic tissues. *Prostate* (2010), 70(13): 1471-1479.
28. Trujillo KA, Heaphy CM, Mai M, Vargas KM, Jones AC, Vo P, Butler K, Joste N, Bisoffi M, Griffith JK. Markers of fibrosis and epithelial to mesenchymal transition demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. *International Journal of Cancer* (2010), 129(6): 1310-1321.
29. Taylor RM, Huber DL, Monson TC, Ali AMS, Bisoffi M, Sillerud LO. Multifunctional iron platinum stealth immunomicelles: targeted detection of human prostate cancer cells using both fluorescence and magnetic resonance imaging. *Journal of Nanoparticle Research* (2011), 13(10): 4717-4729.
30. Taylor RM, Severns V, Brown DC, Bisoffi M, Sillerud LO. Prostate cancer targeting motifs: expression of αv β3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts. *Prostate* (2011), 72(5):523-32.

31. Trujillo KA, Hines WC, Vargas KM, Jones AC, Joste NE, Bisoffi M, Griffith JK. Breast field cancerization: isolation and comparison of telomerase-expressing cells in tumor and tumor adjacent, histologically normal breast tissue. *Molecular Cancer Research* (2011), 9(9): 1209-1221.
32. Fajardo AM, Mackenzie DA, Ji M, Deck LM, Jagt DL, Thompson TA, Bisoffi M. The curcumin analog ca27 down-regulates androgen receptor through an oxidative stress mediated mechanism in human prostate cancer cells. *Prostate* (2012), 72(6): 612-25.
33. Jones AC, Trujillo KA, Phillips GK, Fleet TM, Murton JK, Severns V, Shah SK, Davis MS, Smith AY, Griffith JK, Fischer EG, Bisoffi M. Early growth response 1 and fatty acid synthase expression is altered in tumor adjacent prostate tissue and indicates field cancerization. *Prostate* (2012), 72(11): 1159-70.
34. Trujillo KA, Jones AC, Griffith JK, Bisoffi M. Markers of field cancerization: Proposed clinical applications in prostate biopsies. *Prostate Cancer* (2012): 1-12.
35. Bisoffi M, Severns V, Larson R.S. CTSA-enhanced innovative device development*. Clinical and Translational Science* (2012), 5(4): 311-313.
36. Chen D, Latham JA, Zhao H, Bisoffi M, Farelli JD, Dunaway-Mariano D. Human brown fat inducible thioesterase variant 2 (BFIT2) cellular localization and catalytic function. *Biochemistry* (2012), 51(35):6990-9.
37. Vaughan RA, Garcia-Smith R, Bisoffi M, Trujillo KA, Conn CA. Effects of caffeine on metabolism and mitochondria biogenesis in rhabdomyosarcoma cells compared with 2,4-dinitrophenol. *Nutrition and Metabolic Insights* (2012); 5:59-70.
38. Vaughan RA, Garcia-Smith R, Bisoffi M, Conn CA, Trujillo KA. Conjugated linoleic acid or omega 3 fatty acids increase mitochondrial biosynthesis and metabolism in skeletal muscle cells. *Lipids in Health and Disease* (2012), 11:142.
39. Vaughan RA, Garcia-Smith R, Barberena MA, Bisoffi M, Trujillo KA, Conn CA. Treatment of human muscle cells with popular dietary supplements increase mitochondrial function and metabolic rate. *Nutrition and Metabolism (Lond)* (2012), 9(1):101.
40. Michel V, Licon-Munoz Y, Trujillo KA, Bisoffi M, Parra KJ. Inhibitors of vacuolar ATPase proton pumps inhibit human prostate cancer cell invasion and prostate-specific antigen expression and secretion. *International Journal of Cancer* (2013); 132(2):E1-10.
41. Bisoffi M, Severns V, Branch DW, Edwards TL, Larson RS. Rapid detection of human immunodeficiency virus types 1 and 2 by use of an improved piezoelectric biosensor. *Journal of Clinical Microbiology* (2013), 51(6):1685-91.
42. Vaughan RA, Garcia-Smith R, Bisoffi M, Conn CA, Trujillo KA. Ubiquinol rescues simvastatin-suppression of mitochondrial content, function and metabolism: Implications for statin-induced rhabdomyolysis. *European Journal of Pharmacology* (2013), 711(1-3):1-9.
43. Vaughan RA, Garcia-Smith R, Dorsey J, Griffith JK, Bisoffi M, Trujillo KA. Tumor necrosis factor alpha induces Warburg-like metabolism and is reversed by anti-inflammatory curcumin in breast epithelial cells. *International Journal of Cancer* (2013), 133(10):2504-10.
44. Vaughan RA, Garcia-Smith R, Gannon NP, Bisoffi M, Trujillo KA, Conn CA. Leucine treatment enhances oxidative capacity through complete carbohydrate oxidation and increased mitochondrial density in skeletal muscle cells. *Amino Acids* (2013), 45(4):901-11.
45. Vaughan RA, Garcia-Smith R, Trujillo KA, Bisoffi M. Tumor necrosis factor alpha increases aerobic glycolysis and reduces oxidative metabolism in prostate epithelial cells. *Prostate* (2013), 73(14):1538-46.
46. Vaughan RA, Mermier CM, Bisoffi M, Trujillo KA, Conn CA. Dietary stimulators of the PGC-1 superfamily and mitochondrial biosynthesis in skeletal muscle. A mini-review. *Journal of Physiology and Biochemistry* (2013), 70(1):271-84.
47. Vaughan RA, Gannon NP, Garcia-Smith R, Licon-Munoz Y, Barberena MA, Bisoffi M, Trujillo KA. beta-alanine suppresses malignant breast epithelial cell aggressiveness through alterations in metabolism and cellular acidity in vitro. *Molecular Cancer* (2014), 13(1):14.
48. Solberg NO, Chamberlin R, Vigil JR, Deck LM, Heidrich JE, Brown DC, Brady CI, Vander Jagt TA, Garwood M, Bisoffi M, Severns V, Vander Jagt DL, Sillerud LO. Optical and SPION-enhanced MR imaging shows that trans-stilbene inhibitors

of NF-κB concomitantly lower Alzheimer's disease plaque formation and microglial activation in AβPP/PS-1 transgenic mouse brain. *Journal of Alzheimer's Disease* (2014), 40(1):191-212.
49. Vaughan RA, Gannon NP, Barberena MA, Garcia-Smith R, Bisoffi M, Mermier CM, Conn CA, Trujillo KA. Characterization of the metabolic effects of irisin on skeletal muscle in vitro. *Diabetes Obesity and Metabolism* (2014), 16(8):711-8.
50. Oh D, Nasrolahi Shirazi A, Northup K, Sullivan B, Tiwari RK, Bisoffi M, Parang K. Enhanced cellular uptake of short polyarginine peptides through fatty acylation and cyclization. *Molecular Pharmaceutics* (2014), 11(8):2845-54.
51. Gannon NP, Vaughan RA, Garcia-Smith R, Bisoffi M, Trujillo KA. Effects of the exercise-inducible myokine irisin on malignant and non-malignant breast epithelial cell behavior in vitro. *International Journal of Cancer* (2015), 15;136(4):E197-202.
52. Jones AC, Antillon KS, Jenkins SM, Janos SN, Overton HN, Shoshan DS, Fischer EG, Trujillo KA, Bisoffi M. Prostate field cancerization: Deregulated expression of macrophage inhibitory cytokine 1 (MIC-1) and platelet derived growth factor A (PDGF-A) in tumor adjacent tissue. *PLoS One* (2015), Mar 13; 10(3):e0119314. doi: 10.1371/journal.pone.0119314. eCollection 2015.
53. Gabriel NK, Jones AC, Nguyen JPT, Antillon KS, Janos SN, Overton HN, Jenkins SM, Frisch EH, Trujillo KA, Bisoffi M. Association and regulation of protein factors of field effect in prostate tissues. *International Journal of Oncology* (2016); 49:1541-1552.
54. Vaughan RA, White AC, Beam JR, Gannon NP, Garcia-Smith R, Salgado RM, Bisoffi M, Trujillo KA, Conn CA, Mermier CM. Effect of novel dietary supplement on metabolism *in vitro* and *in vivo*. *Journal of Traditional and Complementary Medicine* (2015); 7(1):1-8. doi: 10.1016/j.jtcme.2015.03.008. eCollection 2017 Jan.
55. Aliabadi HM, Mahdipoor P, Bisoffi M, Hugh JC, Uludağ H. Single and Combinational siRNA Therapy of Cancer Cells: Probing Changes in Targeted and Nontargeted Mediators after siRNA Treatment. *Molecular Pharmaceutics* (2016); 13(12):4116-4128.
56. Lebya K, Garcia-Smith R, Swaminathan R, Jones A, Russell J, Joste N, Bisoffi M, Trujillo K. Towards a personalized surgical margin for breast conserving surgery-Implications of field cancerization in local recurrence. *Journal of Surgical Oncology* (2017); 115(2):109-115.
57. Leyba K, Swaminathan R, Jones A, Russell J, Joste N, Bisoffi M, Trujillo K. Combining the sick lobe theory with markers of field cancerization for refinement of a personalized surgical margin. *Journal of Surgical Oncology* (2017); Jul 17; doi: 10.1002/jso.24724.

Published Abstracts *(published in supplemental in journals reporting on annual meetings)*

1. Bisoffi M., Stephens ND, Chakerian AE, Fore ML, Bryant JE, Moyzis RK, Griffith JK. Effect of telomerase inhibition on telomerase activity, telomere length and growth properties of human tumor cell lines. *Cancer Gene Therapy* (1996), 3: S37.
2. Thalmann GN, Adsan Ö, Klima I, Bisoffi M, Cecchini MG, Studer UE. Peroperative gene-specific primed nested RT-PCR for PSA in 80 patients undergoing radical prostatectomy. *Journal of Urology* (2000), 163 (Suppl.): 180, A7962.
3. Thalmann GN, Adsan Ö, Klima I, Bisoffi M, Cecchini MG, Studer UE. Gene-specific primed reverse transcription (RT) of nested RT-PCR for PSA in prostate cancer staging. *European Urology* (2000), 37 (Suppl.): 117, A467.
4. Thalmann GN, Adsan Ö, Klima I, Bisoffi M, Cecchini MG, Danuser H, Studer UE. Can Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) for Prostate Specific Antigen (PSA) and Prostate Membrane Specific Antigen (PMSA) improve staging and predict biochemical recurrence? *European Urology Supplements* (2002), 1(1), 69.
5. Bisoffi M, Wetterwald A, Peternac D, Studer UE, Cecchini MG, Thalmann GN. Identification by gene array of putative serine/threonine kinase GS3955 upregulated in the LNCaP model of human prostate cancer progression. *Journal of Urology* (2003), 169 (Suppl.): 56.
6. Thalmann G, Sikes R, Bisoffi M, Nelson P, Wetterwald A, Studer U, Cecchini M. Gene expression profiles in the LNCAP model of human prostate cancer progression: Upregulation of osteomimetic peptides. *European Urology Supplements* (2003), *2*(1), 58.

7. Bisoffi M, Wetterwald A, Peternac D, Studer U, Cecchini M, Thalmann G. Identification by gene array and regulation of GS3955 putative serine/threonine kinase in the LNCAP model of human prostate cancer progression. *European Urology Supplements* (2003), 2(1), 59.
8.
9. Holder BS, Bisoffi M, Griffith JK. Is there intra-tumor variability in telomere DNA content in human breast cancer? *FASEB Journal* (2003), 17 (Suppl.): A987-A988.
10. Heaphy CM, Bisoffi M, Fordyce CA, Haaland CJ, Griffith JK: Telomere DNA Content and allelic imbalance in histologically normal tissue adjacent to breast tumors: Implications for prognosis. *International Journal of Cancer* (2003), DOI, 10.
11. Heaphy CM, Bisoffi M, Fordyce CA, Haaland-Pullus CM, Hines WC, Joste NE, Griffith JK. Telomere DNA Content and Allelic Imbalance Predict Disease-free Survival and Define Field Cancerization in Histologically Normal Tissue Adjacent to Breast Tumors. *Breast Cancer Research and Treatment* (2005), 94 (Suppl.): 253.
12. Wyaco JL, Heaphy CM, Bisoffi M, Griffith JK. Prognostic value of allelic imbalance and telomeric DNA in prostate cancer. The *FASEB Journal* (2005), 19, No. 4, pp. A261-A261).
13. Fajardo AM, Hines WC, Griffith JK, Bisoffi M. The role of GS3955 (TRB-2) in prostate cancer. The *FASEB Journal* (2005), 19, No. 4, pp. A310-A310.
14. Sillerud LO, Adolphi NL, Serda R, Bisoffi M, Ji M. Specific MRI Detection of PSMA-expressing Prostate Cancer uisng 3C6 MAb-conjugated SPIONs. *Proceedings of the International Society of Magnetic Resonance in Medicine* 14 (2006).
15. Treat EG, Heaphy CM, Bisoffi M, Griffith JK, Smith AY, Davis MS. Telomere DNA content predicts biochemical recurrence in a retrospective analysis of prostate cancer biopsies. *Journal of Urology* (2007), 177, No. 4, pp. 472-473.
16. Heaphy CM, Treat EG, Fleet TM, Bisoffi M, Smith AY, Davis MS, Fischer EG, Griffith JK. Field effect revealed by 3D-mapping of telomere DNA content and allelic imbalance in whole mount prostates. *Journal of Urology* (2008), 179, 725-725.
17. Haaland Cm, Heaphy CM, Butler KS, Fischer EG, Griffith JK, Bisoffi M. Differential gene expression in tumor adjacent histologically normal prostatic tissue indicates field cancerization. *Proceedings of the American Association for Cancer Research Annual Meeting* (2009), 50, 68.
18. Hodoba NB, Williams TC, Ji M, Bisoffi M. Effect of polyphenolic small molecules on early growth response protein 1 in prostate cancer cells. *Proceedings of the American Association for Cancer Research Annual Meeting* (2009), 50, 428.
19. Fajardo AM, Bowles HJ, MacKenzie DA, Vander Jagt DL, Bisoffi M, Thompson TA. Androgen receptor down-regualtion by curcumin and vitamin E analogues as novel therapeutic strategies for prostate cancer. *Proceedings of the American Association for Cancer Research Annual Meeting* (2009), 50, 579-580.
20. Trujillo KA, Vargas KM, Bisoffi M, Griffith JK. Identification and isolation of telomerase expressing cells from tumor adjacent, histologically normal breast tissue using a novel flow cytometry based method. *Proceedings of the American Association for Cancer Research Annual Meeting* (2009), 50, 842-843.
21. Mai M, Trujillo KA, Vargas KM, Bisoffi M, Griffith JK The inflammatory cytokine TNF-alpha induces rapid, reversible telomere shortening in breast cancer cell lines. *Proceedings of the American Association for Cancer Research Annual Meeting* (2009), 50, 1240-1241.
22. Van Slambrouck S, Bisoffi M, Steelant W. Prostate cancer progression: What is involved? *International Journal of Molecular Medicine* (2010), 26, pp. S8-S8).
23. Fajardo AM, Bowles HJ, MacKenzie DA, Vander Jagt DL, Bisoffi M. Activation of the aryl hydrocarbon receptor and down-regulation of the androgen receptor in prostate cancer cells by the curcumin analog C48. *Proceedings of the American Association for Cancer Research Annual Meeting* (2010), 51, 413.
24. Aguiniga LM, Moreno AY, Bisoffi M. Identification of curcuminoid analogs that down-regulate expression of the early growth response protein 1 in prostate cancer cells. *The FASEB Journal* (2010), 24.
25. Herrera GV, Ernst GL, Aguiniga LM, Moreno AY, Bisoffi M. Identification of curcumin analogs inhibitory of early growth response protein 1 in prostate cancer cells. *The FASEB Journal* (2011), 25, 764-5.

Book Chapters (Invited)

1. Bisoffi M, Heaphy CM, Griffith JK. Field Cancerization in Mammary Tissues; in FIELD CANCERIZATION: BASIC SCIENCE AND CLINICAL APPLICATIONS (Dakubo GD, editor); NOVA Science Publishing, 2011. *ISBN:* 978-1-61761-386-9.
2. Fajardo AM, Bisoffi M. Curcumin, Curcumin Analogs, Oxidative Stress, and Prostate Cancer; in OXIDATIVE STRESS AND DIETARY ANTIOXIDANTS (Preedy VR, editor); Academic Press, Elsevier; 2014. *ISBN-13:* 978-0124052055.

Patents

1. Richard S. Larson, Brian Hjelle, Pamela R. Hall, David C. Brown, Marco Bisoffi, Susan M. Brozik, Darren. W. Branch, Thayne L. Edwards, David Wheeler. "Detection of Bioagents Using a Shear Horizontal Surface Acoustic Wave Biosensor". United States Patent No. 8,709,791 B2: issued on April 29, 2014.

➔ PRESENTATIONS

Oral Presentations

Postgraduate, invited, or extra-Departmental only

1996 Sidney Kimmel Cancer Center Fifth International Conference on Gene Therapy of Cancer, San Diego CA:" Effect of Telomerase Inhibition on Telomerase Activity, Telomere Length and Growth Properties of Human Tumor Cell Lines".

1999 Swiss National Foundation, Annual Meeting of the Somatic Gene Therapy Program, Fribourg, Switzerland: "Genetic Profile of Mouse Tumor Endothelial Cells".

2000 Swiss National Foundation, Annual Meeting of the Somatic Gene Therapy Program, Fribourg, Switzerland: "Genetic Profile of Mouse Tumor Endothelial Cells".

2001 Genitourinary Cancer Research Day, Munich, Germany: "Expression Profiles of the LNCaP Progression Model".

2001 Swiss National Foundation, Annual Meeting of the Somatic Gene Therapy Program, Fribourg, Switzerland: "Scavenger Receptor Block as Strategy for the Identification of Bone Marrow Homing Phages by Panning *in vivo* of Random Peptide Phage Displayed Libraries".

2004 University of New Mexico, Department of Physics, Albuquerque, NM: "Prostate Cancer Progression -Molecular Mechanisms".

2005 National Institutes of Health New Mexico IDeA Network of Biomedical Research Excellence (INBRE) Annual Meeting, Las Vegas NM: "Protein Markers of Prostate Cancer Progression: A (Telomere-Based) Proteomic Approach".

2006 New Mexico Institute of Mining and Technology, Socorro NM: "Identification of Molecular Markers of Prostate and Breast Cancer Progression".

2006 National Institutes of Health New Mexico IDeA Network of Biomedical Research Excellence (INBRE) Annual Meeting, Socorro NM:" Expression Profiles of Prostate Cancer Cells: "… omic" Approaches Towards Biomarker Discovery".

2007 National Institutes of Health New Mexico IDeA Network of Biomedical Research Excellence (INBRE) Annual Meeting, Socorro NM: "Field Cancerization in Breast and Prostate Tissues: Update, Clinical Implications, Future Studies".

2007 National Institutes of Health New Mexico IDeA Network of Biomedical Research Excellence (INBRE) Annual Meeting, Albuquerque NM:" Field Cancerization-A Source for Biomarkers in Prostate and Breast Cancer".

2008 University of New Mexico Hospital, Department of Surgery, Urology Division, Genitourinary Research Day: "Telomere DNA Content in Prostate Biopsies Predicts Early Rise in Prostate Specific Antigen Following Radical Prostatectomy for Prostate Cancer".

2008 University of New Mexico Joint Biomedical Symposium: School of Medicine, College of Pharmacy and School of Engineering, Albuquerque NM: "Detection of Viral Bioagents Using a Shear Horizontal Surface Acoustic Wave Biosensor ".

2009 University of New Mexico Hospital, Department of Surgery, Urology Division, Genitourinary Research Day: "Novel Dual Inhibitors of NF kappa B and the Androgen Receptor in Prostate Cancer Cells".
2010 National Institutes of Health New Mexico IDeA Network of Biomedical Research Excellence (INBRE) Annual Meeting, Santa Fe: "Biomarker and Target Discovery in Human Prostatic Tissues – An Integrated Approach".
2010 University of New Mexico Hospital, Department of Surgery, Urology Division, Genitourinary Research Day: "Evidence for Field Cancerization in the Prostate".
2010 University of New Mexico College of Pharmacy, Albuquerque NM: "Field Cancerization: Molecular Evidence and Clinical Importance".
2010 New Mexico State University, Las Cruces NM: "Field Cancerization: Molecular Evidence and Clinical Importance".
2010 University of New Mexico Health Sciences Center, Department of Pathology, Pathology Grant Rounds, Albuquerque NM: "Field Cancerization: Molecular Evidence and Clinical Importance".
2011 National Institutes of Health New Mexico IDeA Network of Biomedical Research Excellence (INBRE) Bioinformatics Meeting, Santa Fe NM: "Biomarker and Target Discovery in Human Prostatic Tissues – An Integrated Approach".
2011 American Urological Association South Central Section Meeting, San Antonio TX: "Inhibition of Pro-survival Pathways in Prostate Cancer Cells by a Novel Analog of the Natural Product Diferuloylmethane (Curcumin)".
2011 University of New Mexico Hospital, Department of Surgery, Urology Division, Genitourinary Research Day: "Clinical Management of Prostate Cancer-A Biomarker Problem".
2012 National Institutes of Health New Mexico IDeA Network of Biomedical Research Excellence (INBRE) Annual Meeting, Santa Fe: "Biomarker and Target Discovery in Human Prostatic Tissues – An Integrated Approach".
2013 National Institutes of Health New Mexico IDeA Network of Biomedical Research Excellence (INBRE) Annual Meeting, Santa Fe: "Biomarker and Target Discovery in Human Prostatic Tissues – An Integrated Approach".
2014 Chapman University Schmid College of Science and Technology, Science Forum Series: "Using Analogs of the Natural Product Curcumin to Combat Prostate Cancer Cells".
2014 Chapman University School of Pharmacy (CUSP), MSPS Graduate Orientation: "Prostate Field Cancerization" and "The Effect of Curcumin Analogs on Prostate Cancer Cells".
2015 University of California Irvine (UCI) Department of Pathology, Irvine CA: "Prostate Field Cancerization – Molecular Evidence and Clinical Importance".
2015 University of California Irvine (UCI) Chao Family Comprehensive Cancer Center, Genitourinary Disease Oriented Team (GU-DOT), Orange CA: "Prostate Field Cancerization – Molecular Evidence and Clinical Importance".
2016 Osher Lifelong Learning Institute at the California State University Fullerton, Fullerton CA: "Field Cancerization / Field Effect – Thinking Outside The Tumor".
2016 Nicholas Academy, Santa Ana CA: "Telomeres and Such: Aging".
2018 Chapman University School of Pharmacy, Irvine CA: "Field Cancerization – Thinking Outside the Tumor".

Poster Presentations

Since joining UNM in 2002, primary author, senior author, mentor, or co-mentor <u>only</u>; extra-Institutional <u>only</u>

2003 National Institutes of Health (NIH) Innovative Emerging Analysis Technologies (IMAT) Annual Meeting, San Diego CA:" Telomere DNA content predicts clinical outcome in prostate and breast cancer". Bisoffi M, Fordyce CA, Mangalik A, Joste NE, Griffith JK.
2004 Annual Iberoamerican Research and Development Summit (AIRDS), Albuquerque NM: "Diagnosis and prognosis of cancer: A simple high-throughput method for measuring the extent of genomic instability in tissue samples". Heaphy CM, Hines WC, Bisoffi M, Griffith JK.
2004 American Urological Association (AUA) Annual Meeting, San Franscisco CA: "Telomere DNA content is associated with disease-free survival in prostate cancers". Fordyce CA, Joste NE, Smith AY, Bisoffi M, Griffith JK.
2005 Department of Defense (DOD) Prostate Cancer Roadmap to the Future Conference, Niagara Falls NY: "Expression profiles of androgen-independent bone metastatic prostate cancer cells indicate a role for the kinase-Like Tribbles proteins in prostate cancer progression". Bisoffi M, Fajardo AM, Hines WC, Ji M, Klima I, Griffith JK, Thalmann GN.

2005 American Society of Biochemistry and Molecular Biology (ASBMB) Annual Meeting, San Diego CA: "The role of GS3955 (TRB-2) in prostate cancer". Fajardo A, Hines WC, Griffith JK, Bisoffi M.

2005 Department of Defense (DOD) Era of Hope Meeting, Philadelphia PA: "Telomere DNA content and allelic imbalance in histologically normal tissue adjacent to breast tumors". Heaphy CM, Bisoffi M, Fordyce CA, Mangalik A, Griffith JK.

2005 San Antonio Breast Cancer Symposium, San Antonio TX: "Field cancerization in histologically normal tissue adjacent to breast tumors as determined by telomere DNA content and allelic imbalance". Heaphy CM, Bisoffi M, Fordyce CA, Haaland-Pullus CM, Hines WC, Joste E, Griffith JK.

2005 Society for Basic Urologic Research (SBUR) Annual Meeting, Miami FL: "Expression profiles of androgen-independent bone metastatic prostate cancer cells indicate a role for the kinase-Like Tribbles proteins in prostate cancer progression". Bisoffi M, Fajardo AM, Hines WC, Ji M, Klima I, Thalmann GN.

2006 National Institutes of Health (NIH) IDeA Network of Biomedical Research Excellence (INBRE) AnnualMeeting, Washington DC: "Expression profiles of androgen-independent bone metastatic prostate cancer cells: Genomic and proteomic approaches towards biomarker discovery". Fajardo AM, Ji M, Johnson RC, Buckley RT, Bisoffi M.

2007 Society of Toxicology (SOT) Mountain West Regional Chapter Meeting, Charlotte NC: "Identification of curcumin analogs toxic against prostate cancer cells through inhibition of the pro-survival nuclear factor kappa B transcription factor". Fajardo A, Hunsaker L, Deck L, Vander Jagt D, Thompson T, Bisoffi M.

2007 Department of Defense (DOD) Innovative Minds in Prostate Cancer Today Meeting, Atlanta GA: "Allelic imbalance in prostatectomy tissues correlates with pathological Gleason score and predicts clinical outcome". Bisoffi M, Heaphy CM, Griffith JK.

2008 Society of Toxicology (SOT) Mountain West Regional Chapter Meeting, Salt Lake City UT: "Disruption of androgen receptor activity agents that downregulate androgen receptor expression in prostate cancer cells". Fajardo A, MacKenzie D, Deck L, Vander Jagt D, Bisoffi M, Thompson T.

2008 American Urological Association (AUA) Annual Meeting, Orlando FL: "Field effect revealed by 3D-mapping of telomere DNA content and allelic imbalance in whole mount prostates". Heaphy CM, Treat EG, Fleet TM, Bisoffi M, Smith AY, Davis MS, Fischer EG, Griffith JK.

2008 Center for Integrated Nanotechnologies (CINT) of the Los Alamos National Laboratories, Research Day, Albuquerque NM: "Investigating telomere structure and function by atomic force microscopy and fluorescence microscopy". Goodwin E, Goodwin P, Martinez J, Phipps L, Blagoev K, Keller D, Griffith J, Bisoffi M.

2008 Department of Defense (DOD) Era of Hope Meeting, Baltimore MD:" Assessing the extent of allelic imbalance in human breast tissue using a multiplex PCR system". Heaphy CM, Bisoffi M, Joste NE, Baumgartner KB, Baumgartner RN, Griffith JK.

2008 National Institutes of Health (NIH) New Mexico IDeA Network of Biomedical Research Excellence (INBRE) Bioinformatics Meeting, Santa Fe NM: "Markers of prostate cancer progression: A proteomic approach". Higgins KJ, Bisoffi M

2008 National Institutes of Health (NIH) New Mexico IDeA Network of Biomedical Research Excellence (INBRE) Bioinformatics Meeting, Santa Fe NM: "Identification of curcumin analogs toxic against prostate cancer cells through inhibition of the pro-survival nuclear factor kappa B transcription factor". Fajardo A, Hunsaker L, Deck L, Vander Jagt D, Thompson T, Bisoffi M.

2009 Society of Toxicology (SOT) Mountain West Regional Chapter Meeting, Salt Lake City UT: "Activation of the aryl hydrocarbon receptor by tocopheryl-quinone in human prostate cancer cells". Fajardo A, Bowles H, MacKenzie D, Bisoffi M, Thompson T.

2009 American Association of Cancer Research (AACR) Annual Meeting, Denver CO: "Differential gene expression in tumor adjacent histologically normal prostatic tissue indicates field cancerization". Haaland CM, Heaphy CM, Butler KS, Fischer EG, Griffith JK, Bisoffi M.

2009 American Association of Cancer Research (AACR) Annual Meeting, Denver CO: "Differential mechanisms of androgen receptor downregulation by curcumin and vitamin E analogs in prostate cancer cells". Fajardo A, Bowles H, MacKenzie D, Vander Jagt D, Bisoffi M, Thompson T.

2009 American Association of Cancer Research (AACR) Annual Meeting, Denver CO: "Effect of polyphenolic small molecules on early growth response protein 1 in prostate cancer cells". Hodoba NB, Williams TC, Ji M, Bisoffi M.

2009 Society for Basic Urologic Research (SBUR) Annual Meeting, New Orleans LA: "Curcuminoid small molecule inhibitors of androgen receptor and nuclear factor kappab B in prostate cancer cells". Fajardo AM, Deck LM, Vander Jagt DL, Thompson TA, Bisoffi M.

2009 National Institute of Diabetes and Digestive and Kidney (NIDDK) Undergraduate Short-Term Education Program for Underrepresented Persons (STEP-UP) Meeting, Los Angeles CA: "Construction of an Egr-1 promoter driven green fluorescence protein reporter for prostate cancer cells". Garcia B, Bisoffi M.

2010 American Association of Cancer Research (AACR) Annual Meeting, Washington DC: "Curcumin analog C48 activates the aryl hydrocarbon receptor and down-regulates the expression of androgen receptor". Fajardo A, Bowles H, MacKenzie D, Vander Jagt D, Bisoffi M, Thompson T.

2010 American Association of Cancer Research (AACR) Annual Meeting, Washington DC: "Multifunctional iron platinum micelle contrast agents for the specific detection of prostate cancer". Taylor RM, Huber DL, Monson TC, Ali AMS, Bisoffi M, Sillerud LO.

2010 American Society of Biochemistry and Molecular Biology (ASBMB) Annual Meeting, Anaheim CA: "Development of a green fluorescent protein reporter for the identification of small molecule inhibitors of the early growth response protein 1 in prostate cancer cells". Aguiniga LM, Moreno AY, Vander Jagt DL, Deck LM, Bisoffi M.

2010 National Institutes of Health (NIH) New Mexico IDeA Network of Biomedical Research Excellence (INBRE) Annual Meeting, Santa Fe NM: "Development of a green fluorescent protein reporter for the identification of small molecule inhibitors of the early growth response protein 1 in prostate cancer cells". Aguiniga LM, Moreno AY, Vander Jagt DL, Deck LM, Bisoffi M.

2010 National Institutes of Health (NIH) New Mexico IDeA Network of Biomedical Research Excellence (INBRE) Annual Meeting, Santa Fe NM: " Presence of early growth response protein-1 in tumor adjacent histologically normal prostatic tissue provides evidence for field cancerization:. Jones AC, Trujillo KA, Fleet TM, Fischer EG, Joste NE, Smith AY, Davis MS, Griffith JK, Bisoffi M.

2010 Society for the Advancement of Chicanos and Native Americans in Science (SACNAS) Annual Meeting, Anaheim CA: "Proteomic characterization of human prostatic field cancerization". Candelaria L, Severns V, Fleet T, Mobarak C, Bisoffi M.

2011 National Institutes of Health (NIH) New Mexico IDeA Network of Biomedical Research Excellence (INBRE) Bioinformatics Meeting, Santa Fe NM: "Improved diagnosis and prognosis of prostate cancer using markers of field cancerization". Jones AC, Fischer EG, Smith AY, Griffith JK, Bisoffi M.

2011 American Association of Cancer Research (AACR) Annual Meeting, Orlando FL: "Curcumin analog 27 induces reactive oxygen species mediate loss of androgen receptor protein expression in human prostate cancer cells". Fajardo A, MacKenzie D, Vander Jagt DL, Deck L , Thompson T, Bisoffi M.

2011 American Society of Biochemistry and Molecular Biology (ASBMB) Annual Meeting, Washington DC: "Identification of curcumin analogs inhibitory of early growth response protein 1 in prostate cancer cells". Herrera GV, Ernst GL, Aguiniga LM, Bisoffi M.

2011 Department of Defense (DOD) Innovative Minds in Prostate Cancer Today Meeting, Orlando FL: "Prognostic value of allelic imbalance in prostate biopsy tissues". Heaphy CM, Bisoffi M,Griffith JK.

2011 Department of Defense (DOD) Innovative Minds in Prostate Cancer Today Meeting, Orlando FL: "Differential gene expression in tumor adjacent histologically normal prostatic tissue indicates field cancerization". Haaland CM, Heaphy CM, Jones AC, Butler KS, Fleet TM, Fischer EG, Smith AY, Griffith JK, Bisoffi M.

2011 Department of Defense (DOD) Innovative Minds in Prostate Cancer Today Meeting, Orlando FL: "Curcumin analog c48 inhibits nuclear factor kappa B and androgen receptor function in prostate cancer cells". Fajardo AM, MacKenzie DA, Deck LM, Vander Jagt DL, Thompson TA, Bisoffi M.

2012 American Medical Women's Association (AMWA) Annual Meeting, Miami FL: "Early Growth Response 1 and Fatty Acid Synthase Expression is Altered in Tumor Adjacent Prostate Tissue and Indicates Field Cancerization". Jones AC, Bisoffi M.

2014 Beta Beta Beta (Tri Beta) Biological Honor Society, Chapman University ~ Epsilon Mu Meeting, Orange CA: "Molecular Insights into Prostate Field Cancerization: Are Oxidative Stress and Telomerase Inhibition Functionally Linked to Induction of Early Growth Response 1 and Macrophage Inhibitory Cytokine 1?" Gabriel KN, Frisch EH, Bisoffi M.

2014 Beta Beta Beta (TriBeta) Research Conference at Chapman University, Orange CA: "Molecular insights into prostate field cancerization: Are oxidative stress and telomerase inhibition functionally linked to induction of Early Growth Response 1 and Macrophage Inhibitory Cytokine 1?" Gabriel K, Frisch E, Bisoffi M.

2014 University of California at Irvine (UCI) Chao Family Comprehensive Cancer Center Annual Retreat, Palm Springs CA: "Protein markers of prostate field cancerization - elevated expression in histologically normal tissues adjacent to prostate tumors". Bisoffi M.

2014 University of California Irvine (UCI) Chao Family Comprehensive Cancer Center Annual Retreat, Palm Springs CA: "Early growth response 1 expression in prostate tissues indicates field cancerization". Shoshan DS, Bisoffi M.

2014 Southern California Conferences for Undergraduate Research (SCCUR), Fullerton CA: "Molecular insights into prostate field cancerization: Are oxidative stress and telomerase inhibition functionally linked to induction of Early Growth Response 1 and Macrophage Inhibitory Cytokine 1?" Gabriel K, Frisch E, Bisoffi M.

2015 Beta Beta Beta (TriBeta) Research Conference in Monterey Bay CA: "Molecular insights into prostate field cancerization". Frisch E, Bisoffi M.

2015 University of California at Irvine (UCI) Chao Family Comprehensive Cancer Center Annual Retreat, Palm Springs CA: "Elucidating molecular pathways of prostate field cancerization: Potential role of EGR-1 as a master regulator". Gabriel K, Bisoffi M.

2015 University of California at Irvine (UCI) Chao Family Comprehensive Cancer Center Annual Retreat, Palm Springs CA: "Exploring the anti-androgenic effects of diarylpentanoids". Bisoffi M.

2016 University of California at Irvine (UCI) Chao Family Comprehensive Cancer Center Annual Retreat, Long Beach CA: "Determining the role of the androgen receptor in pancreatic cancer cell models". Miyake T, Sylvester C, Rowland-Goldsmith M, Bisoffi M.

2016 University of California at Irvine (UCI) Chao Family Comprehensive Cancer Center Annual Retreat, Long Beach CA: "Determining the Role of Exosomes in Prostate Field Cancerization". Nguyen J, Bisoffi M.

2017 American Chemical Society (ACS) Southern California Undergraduate Research Conference (SCURC) at the University of California Los Angeles, Los Angeles CA: "Structure activity relationships of a diarylpentanoid which induces reactive oxygen species in prostate cancer cells". Sanyal R, Bisoffi M.

2017 Beta Beta Beta (TriBeta) Pacific District Convention, Livermore CA: "Association between cancer exosomes and prostate filed cancerization". Pytak P, Bisoffi M.

2017 American Association of Pharmaceutical Scientists (AAPS) National Meeting, San Diego CA: Fibronectin-targeted peptide anticancer drug conjugates for prostate cancer". Park SE, Kristedja T, Darwish S, Bisoffi M, Parang K, Tiwari R.

2017 253rd American Chemical Society (ACS) National Meeting & Exposition, San Francisco CA: "Design and synthesis of fibronectin-targeted peptide anticancer drug conjugates for targeted chemotherapy of prostate cancer. Park SE, Kristedja T, Bisoffi M, Parang K, Tiwari R.

2018 American Society for Biochemistry and Molecular Biology Annual Meeting, San Diego CA. "Using an innovative approach to teach students how to communicate about scientific topics to non-scientists". Rowland-Goldsmith M, Bisoffi M.

➔ REFERENCES

1. **Dr. Andrew Lyon (PhD)**, Chapman University, Schmid College of Science and Technology, Orange CA, 92866, USA. Dean. 2014-2018. lyon@chapman.edu

2. **Dr. Jeffrey K. Griffith (PhD)**, University of New Mexico School of Medicine, Albuquerque NM, 87131, USA. Chair, Executive Dean, research and career mentor. 1996-1998 and 2002-2013. jkgriffith@salud.unm.edu

3. **Dr. Anthony Y. Smith (MD)**, University of New Mexico School of Medicine and Veterans Affairs Health Care, Albuquerque NM, 87131, USA. Collaborator, project advisor, consultant. 2004-2013. aysmith@salud.unm.edu

4. **Dr. Helen J. Hathaway (PhD),** University of New Mexico School of Medicine, Albuquerque NM, 87131, USA. Collaborator and research consultant. 2004-2013. hhathaway@salud.unm.edu

5. **Dr. William L. Anderson (PhD)**, University of New Mexico School of Medicine, Albuquerque NM, 87131, USA. Chair. 2008-2012. billand@unm.edu

6. **Dr. Melanie E. Royce (MD, PhD)**, University of New Mexico School of Medicine and Cancer Center, Albuquerque NM, 87131, USA. Project advisor, consultant. 2001-2013. mroyce@salud.unm.edu

7. **Dr. George N. Thalmann (MD)**, University of Bern and Inselspital, 3010 Bern, Switzerland. Research and career mentor. 1998-2002. george.thalmann@insel.ch

8. **Dr. Bruno Betschart (PhD)**, Université de Neuchâtel, 2007 Neuchâtel, Switzerland. Research mentor. 1990-1995. bruno.betschart@unine.ch

9. **Dr. Murray E. Selkirk (PhD)**, Imperial College of Science, Technology and Medicine, London SW7 2AZ, UK. Research mentor. 1991. m.selkirk@imperial.ac.uk